Telo Genomics Corp (TSE:TELO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Telo Genomics Corp has successfully closed an oversubscribed private placement, raising $2.5 million through the sale of 25,459,000 units. The funds will support the commercialization of its cancer diagnostic products, including TeloViewSMM, and the development of new tests. This financial boost reflects investor confidence in Telo’s strategic plans and growth potential.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
